• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

In vivo Molecular Mechanism of Human CYP3A Induction Involved in Drug Interaction

Research Project

Project/Area Number 12672207
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field 応用薬理学・医療系薬学
Research InstitutionTohoku University

Principal Investigator

NAGATA Kiyoshi  Tohoku University, Graduate School of Pharmaceutical Sciences, Associate Professor, 大学院・薬学研究科, 助教授 (80189133)

Co-Investigator(Kenkyū-buntansha) MIYATA Masaaki  Tohoku University, Graduate School of Pharmaceutical Sciences, Assistant, 大学院・薬学研究科, 助手 (90239418)
Project Period (FY) 2000 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥3,800,000 (Direct Cost: ¥3,800,000)
Fiscal Year 2001: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 2000: ¥2,100,000 (Direct Cost: ¥2,100,000)
KeywordsP450 / CYP3A4 / Induction / Adenovirus / human / in vivo / cis-element / Nuclear Receptor / cis-element / CYP3A1 / PXR / nuclear receptor / rat
Research Abstract

Cytochrome P450s including in the CYP3A subfamily are involved in metabolism of numbers of clinically relevant substrates as well as numerous endogenous compounds. CYP3A forms are induced by treatment with various drugs, but those induction profiles differ between experimental animals and humans. Recently, a novel orphan receptor, pregnane X receptor (PXR) has been isolated and reported to make a heterodimer with retinoid X receptera (RXRa). In our experiment, co-expression of human PXR (hPXR) with RXRa did not show the CYP3A1 gene activation by treatment with rifampicin. When hPXR co-expressed with other orphan receptors, COUPs, apolipoprotein AI regulatory protein 1 (ARP-1) and v-ErbA-related protein 3, the CYP3A1 gene expression was activated by rifampicin in HepG2 cells. On the contrary, neither co-expression of PXR with RXRa nor with COUPs showed the CYP3A4 gene activation by the treatment, although the activation was observed on single expression of hPXR in HepG2 cells. On the ot … More her hand, both CYP3A1 and CYP3A4 inductions through hPXR activation by rifampicin were basically similar at the level of their cis-elements. The transactivation of the CYP3A4 gene is mainly mediated through dNR-1 locating around at its -7600 bp and enhance through ER-6. To further verify the in vivo activation of the CYP3A4 gene expression by drugs, adenovirus expression vectors, AdCYP3A4-362 and AdCYP3A4-362-7k, were constructed with the proximal promoter (+11 to -364) and the enhancer (-7.2 k to -7.8 k) regions of the CYP3A4 gene, respectively. AdCYP3A4-362 infection to HepG2 cells showed the CYP3A4 gene activation by treatment with clotrimazole and dexamethsone. The gene activation was enhanced by co-infection of AdhPXR. AdCYP3A4-362-7k infection to HepG2 cells showed the CYP3A4 gene activation not only by clotrimazole but also by rifampicin. Therefore in vivo experiment of the CYP3A4 gene activation by use of AdCYP3A4-362-7k was carried out in mouse and rat. Strong CYP3A4 gene activation was observed in mouse livers by administration of all drugs used in this experiment. The activation was strongly enhanced in both animal livers treated only with rifampicin by co-transfection of AdhPXR. These results suggest that PXR is one of essential factors for the CYP3A induction, and others factors are also predicted from our experiment. Less

Report

(3 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report
  • Research Products

    (14 results)

All Other

All Publications (14 results)

  • [Publications] M.Ogino, K.Nagata, Y.Yamazoe: "Selective suppression of human CYP3A form, CYP3A7, by troglitazone in HeDG2 cells"Drug Metab. Pharmacokin. 17. 42-46 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] M.Furukawa, T.Okubo, M.Ogino, T.Yamazaki, M.Shimada, K.Nagata, Y.Yamazoe: "Adenovirus vector-mediated reporter system for in vivo analysis of the human CYP3A4 gene activation"J. Biochem.. 131. 71-78 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 永田 清, 荻野淳, 山崎 亨, 大久保貴之, 高田智成, 古川正幸, 山添 康: "ヒトCYP3A4誘導の分子機構"薬物動態. 16. 485-490 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 永田 清, 山添 康: "CYP3A4の発現とPXR"月刊薬事. 43. 512-519 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 荻野淳, 永田清, 山添康: "薬物によるCYP3A誘導の分子機序とその種差"薬物動態. 15. 52-56 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] M. Ogino, K. Nagata, Y. Yamazoe.: "Selective suppression of human CYP3A form, CYP3A7, by troglitazone in HepG2 cells"Drug Metab. Pharmacokin.. 17. 42-46 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] M. Furukawa, T. Okubo, M. Ogino, T. Yamazaki, M. Shimada, K. Nagata, Y. Yamazoe: "Adenovirus vector-mediated reporter system for in vivo analysis of the human CYP3A4 gene activation"J Biochem.. 131. 71-78 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Nagata, Y. Yamazoe: "Regulation of CYP3A4 expression and PXR"Pharmaceuticals Monthly. 43. 512-519 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] K. Nagata, M. Ogino, T. Yamazaki, T. Okubo, T. Takada, M. Furukawa, Y. Yamazoe: "Molecular Mechanism of Human CYP3A4 Induction"Xenotio. Metabol. and Dispos.. 16. 485-490 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] M. Ogino, K. Nagata, Y. Yamazoe: "Molecular Mechanisms of CYP3A gene Transactivations by Chemicals and their Species Differences"Xenotio. Metabol. and Dispos.. 15. 52-56 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] M.Ogino, K.Nagata, Y.Yamazoe: "Selective suppression of human CYP3A form, CYP3A7, by troglitazone in HepG2 cells"Drug Metab. Pharmacokin. 17. 42-46 (2002)

    • Related Report
      2001 Annual Research Report
  • [Publications] .M.Furukawa, T.Okubo, M.Ogino, T.Yamazaki, M.Shimada, K.Nagata, Y.Yamazoe: "Adenovirus vector-mediated reporter system for in vivo analysis of the human CYP3A gene activation"J. Biochem.. 131. 71-78 (2002)

    • Related Report
      2001 Annual Research Report
  • [Publications] 永田 清、荻野淳、山崎 亨、大久保貴之、高田智成、古川正幸、山添 康: "ヒトCYP3A誘導の分子機構"薬物動態. 16. 485-490 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 永田清: "CY3A4の発現調節とPXR"日刊薬事. 2月臨時増刊号. 120-127 (2001)

    • Related Report
      2000 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi